Enanta Pharmaceuticals, Inc.
330 articles about Enanta Pharmaceuticals, Inc.
-
Enanta Pharmaceuticals, Inc. To Present At The 39th Annual Deutsche Bank Securities Healthcare Conference
4/30/2014
-
Enanta Pharmaceuticals, Inc. To Host Conference Call To Discuss Financial Results For The Fiscal Second Quarter And Six Months Ended March 31, 2014
4/28/2014
-
Enanta Pharmaceuticals, Inc. Announces New Drug Application Submission To The FDA For All-Oral, Interferon-Free Hepatitis C Regimen
4/22/2014
-
Enanta Pharmaceuticals, Inc. Announces Detailed Data From TURQUOISE-II Study In Chronic Hepatitis C Patients With Cirrhosis Being Presented At The European Association For The Study Of The Liver (EASL) Meeting
4/14/2014
-
Enanta Pharmaceuticals, Inc. Announces Data Presentations On Regimens Containing Protease Inhibitor ABT-450 To Be Presented At The European Association For The Study Of The Liver (EASL) Meeting
3/24/2014
-
Enanta Pharmaceuticals, Inc. Announces New Data Presented On Protease Inhibitor ABT-493 At The 21st Conference On Retroviruses And Opportunistic Infections (CROI)
3/5/2014
-
Enanta Pharmaceuticals, Inc. Release: PEARL-III Study Results In Patients With Chronic Hepatitis C Presented At The 21st Conference On Retroviruses And Opportunistic Infections (CROI)
3/3/2014
-
Enanta Pharmaceuticals, Inc. Reports Financial Results For Its Fiscal First Quarter Ended December 31, 2013
2/13/2014
-
Enanta Pharmaceuticals, Inc. Announces The Appointment Of George S. Golumbeski, Ph.D. To Board Of Directors
2/11/2014
-
Enanta Pharmaceuticals, Inc. To Present At The 2014 Leerink Swann and Company Global Healthcare Conference Presentation To Be Webcast On February 13, 2014 at 2:15 P.M. ET
2/6/2014
-
Enanta Pharmaceuticals, Inc. Announces The Appointment Of Timothy D. Ocain, Ph.D. As Senior Vice President, New Product Strategy And Development
2/4/2014
-
Enanta Pharmaceuticals, Inc. Announces Results From Four All-Oral, Interferon-Free, Phase 3 Studies For The Treatment Of Genotype 1 Hepatitis C Virus Infection
1/31/2014
-
Enanta Pharmaceuticals, Inc., No Longer Obscure, Eyes Slice Of Big Hepatitis C Market
1/24/2014
-
Enanta Pharmaceuticals, Inc. Initiates Phase 1 Study Of MRSA Infection Candidate EDP-788
1/13/2014
-
Enanta Pharmaceuticals, Inc. To Present At The 32nd Annual J.P. Morgan Healthcare Conference
1/6/2014
-
Enanta Pharmaceuticals, Inc. Announces The Appointment Of Bruce L.A. Carter, Ph.D. To Board Of Directors
11/25/2013
-
AbbVie, Enanta Pharmaceuticals, Inc.'s Hepatitis C Treatment Helps 96 Percent Of Patients In Phase 3 Studies
11/19/2013
-
Enanta Pharmaceuticals, Inc. To Host Conference Call To Discuss Financial Results For The Fiscal Fourth Quarter And Year Ended September 30, 2013
11/15/2013
-
Enanta Pharmaceuticals, Inc. to Present at the 2013 Credit Suisse Healthcare Conference
11/7/2013
-
Enanta Pharmaceuticals, Inc. Release: New GT-1b Data From ABT-450 Containing Regimen Being Presented at The Liver Meeting
11/4/2013